Press releasesKeep up with the latest news from Ikena Oncology.January 5, 2021 Ikena Oncology Closes $120 Million Series B Financing Led by Omega FundsNovember 19, 2020 Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory BoardNovember 9, 2020 Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual MeetingAugust 18, 2020 Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical OfficerAugust 12, 2020 Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR BlockadeJune 22, 2020 Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling PathwayJanuary 28, 2020 Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid TumorsDecember 3, 2019 Kyn Therapeutics Rebrands as Ikena Oncology, Reflecting Next Phase of Growth 12>>Access our media kit page to view and download assorted corporate assets.View Media Kit
